Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock
Portfolio Pulse from Benzinga Insights
Analysts have varied opinions on Zevra Therapeutics (NASDAQ:ZVRA), with most being bullish. Recent price targets average $19.71, up from $18.17. Despite positive analyst sentiment, Zevra faces financial challenges, including declining revenue and high debt.
September 24, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zevra Therapeutics has received mostly bullish ratings from analysts, with an average price target of $19.71. However, the company faces significant financial challenges, including a 47.47% revenue decline and high debt levels.
While analysts are bullish on ZVRA with increased price targets, the company's financial metrics such as declining revenue, negative net margin, and high debt-to-equity ratio present significant challenges. This mixed outlook results in a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100